Bharat Biotech to acquire Chiron Behring from GSK

Chiron Behring is a WHO (World Health Organisation) pre-qualified manufacturer of rabies vaccines, eligible for supplies to United Nations agencies and has product registrations in over 20 countries.

Refusing to share the financial details of the deal, the company said that it would recover the investment in the next five years. (Representational Image)

Vaccine manufacturer Bharat Biotech will be acquiring 100 per cent equity stake in Chiron Behring Vaccines in an all-cash transaction from GlaxoSmithKline Asia for an undisclosed sum in the coming weeks.

Refusing to share the financial details of the deal, the company said that it would recover the investment in the next five years. The company hopes to become the world’s largest rabies vaccine manufacturer in the next few years having an annual capacity of 25 million doses.

Chiron Behring is a WHO (World Health Organisation) pre-qualified manufacturer of rabies vaccines, eligible for supplies to United Nations agencies and has product registrations in over 20 countries.

Story continues below this ad

Chiron Behring Vaccines was formed as a result of the purchase of the vaccines business of Hoechst by Chiron Corporation United States.

It is one of the largest manufacturers of high-quality rabies vaccines in the world. FE